Citations (38)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Uwe Klaus Zettl, Michael Hecker, Orhan Aktas, Torsten Wagner & Paulus S. Rommer. (2018) Interferon β-1a and β-1b for patients with multiple sclerosis: updates to current knowledge. Expert Review of Clinical Immunology 14:2, pages 137-153.
Read now
Read now
Eleonora Cocco, Alberto Caoci, Lorena Lorefice & Maria Giovanna Marrosu. (2017) Perception of risk and shared decision making process in multiple sclerosis. Expert Review of Neurotherapeutics 17:2, pages 173-180.
Read now
Read now
Bernd C Kieseier. (2014) The challenges of measuring disability accumulation in relapsing–remitting multiple sclerosis: evidence from interferon beta treatments. Expert Review of Neurotherapeutics 14:1, pages 105-120.
Read now
Read now
Mark Cascione, Daniel Wynn, Luigi M. Barbato, Linda Pestreich, Lesley Schofield & Kevin McCague. (2013) Randomized, open-label study to evaluate patient-reported outcomes with fingolimod after changing from prior disease-modifying therapy for relapsing multiple sclerosis: EPOC study rationale and design. Journal of Medical Economics 16:7, pages 859-865.
Read now
Read now
Articles from other publishers (34)
Katelijn M. Blok, Joost van Rosmalen, Nura Tebayna, Joost Smolders, Beatrijs Wokke & Janet de Beukelaar. (2023) Disease activity in primary progressive multiple sclerosis: a systematic review and meta-analysis. Frontiers in Neurology 14.
Crossref
Crossref
Monty CuthbertMarta Lewandowska, Laura FreemanConor DevineKaren LeeShireen Kassam. (2022) The Impact of Stopping Medications and Introducing a Whole Food Plant-Based Diet on Patients Living with Multiple Sclerosis – A Report of Two Cases. American Journal of Lifestyle Medicine 17:2, pages 206-212.
Crossref
Crossref
Ali Moghtaderi, Malihe Shahidi-Pourakbari, Shahrokh Izadi, Alireza Khosravi & Zabihollah Hashemzehi. (2023) Ongoing increase in incidence and prevalence of multiple sclerosis in south-eastern Iran: A three decade study. Multiple Sclerosis and Related Disorders 71, pages 104557.
Crossref
Crossref
Matthijs M. Versteegh, Simone A. Huygens, Beatrijs W.H. Wokke & Joost Smolders. (2022) Effectiveness and Cost-Effectiveness of 360 Disease-Modifying Treatment Escalation Sequences in Multiple Sclerosis. Value in Health 25:6, pages 984-991.
Crossref
Crossref
Alexandra Simbrich, Jasmine Thibaut, Laura Khil, Stanislav Maximov, Heinz Wiendl, Klaus Berger, Luisa Klotz, Florian Stögbauer, Orhan Aktas, Tjalf Ziemssen, Frauke Zipp, Antonios Bayas, Thomas Müller, Friedemann Paul, Maria Seipelt, Klemens Angstwurm, Martin Weber, Brigitte Wildemann, Tania Kümpfel, Christoph Ruschil, Matthias Grothe, Iris Steck, Christoph Heesen, Uwe Zettl, Refik Pul, Hayrettin Tumani, Matthias Kaste, Frank A. Hoffmann, Wolfgang Freund, Peter Schwenkreis, Annette Walter, Frank Halbgewachs, Florian Bethke, Michael Hotz, Stefan Harscher, Ralf-Jochen Kuhlmann, Cordula Haltenhof, Muhterem Erinola, Jörg Berrouschot, Isabell Greeve, Felicitas Heidler, Michael Mandrysch, Wolfgang Kusch, Alexander Niklas, Hela-Felicitas Petereit, Jonas Repenthin, Martin Brand, Heike Stephanik & Roland Bauer. (2020) Chances and Challenges of Registry-Based Pharmacovigilance in Multiple Sclerosis: Lessons Learnt from the Implementation of the Multicenter REGIMS Registry. Drug Safety 44:1, pages 7-15.
Crossref
Crossref
Natalie A Schwehr, Karen M Kuntz, Mary Butler, Eva A Enns, Nathan D Shippee, Elaine Kingwell, Helen Tremlett & Adam F Carpenter. (2019) Age-related decreases in relapses among adults with relapsing-onset multiple sclerosis. Multiple Sclerosis Journal 26:12, pages 1510-1518.
Crossref
Crossref
Michael J. Asmussen, Marita E. Mauracher, Onutobor Omu, Sandro R. Nigg & Scott E. Jarvis. (2020) Reliability and validity of a novel device for quantifying ankle dorsiflexion force in persons with multiple sclerosis. Multiple Sclerosis and Related Disorders 40, pages 101940.
Crossref
Crossref
Pierre de Flon, Katarina Laurell, Peter Sundström, Kaj Blennow, Lars Söderström, Henrik Zetterberg, Martin Gunnarsson & Anders Svenningsson. (2019) Comparison of plasma and cerebrospinal fluid neurofilament light in a multiple sclerosis trial. Acta Neurologica Scandinavica 139:5, pages 462-468.
Crossref
Crossref
Yinan Zhang, Amber Salter, Erik Wallström, Gary Cutter & Olaf Stüve. (2019) Evolution of clinical trials in multiple sclerosis. Therapeutic Advances in Neurological Disorders 12, pages 175628641982654.
Crossref
Crossref
Anthony Traboulsee, David K. B. Li, Mark Cascione, Juanzhi Fang, Fernando Dangond & Aaron Miller. (2018) Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing–remitting multiple sclerosis at year 1. BMC Neurology 18:1.
Crossref
Crossref
Anthony Traboulsee, David K. B. Li, Mark Cascione, Juanzhi Fang, Fernando Dangond & Aaron Miller. (2018) Predictive value of early magnetic resonance imaging measures is differentially affected by the dose of interferon beta-1a given subcutaneously three times a week: an exploratory analysis of the PRISMS study. BMC Neurology 18:1.
Crossref
Crossref
Carmen Tur, Marcello Moccia, Frederik Barkhof, Jeremy Chataway, Jaume Sastre-Garriga, Alan J. Thompson & Olga Ciccarelli. (2018) Assessing treatment outcomes in multiple sclerosis trials and in the clinical setting. Nature Reviews Neurology 14:2, pages 75-93.
Crossref
Crossref
Clare Baecher-Allan, Belinda J. Kaskow & Howard L. Weiner. (2018) Multiple Sclerosis: Mechanisms and Immunotherapy. Neuron 97:4, pages 742-768.
Crossref
Crossref
Caspar E. P. van Munster & Bernard M. J. Uitdehaag. (2017) Outcome Measures in Clinical Trials for Multiple Sclerosis. CNS Drugs 31:3, pages 217-236.
Crossref
Crossref
Luca Prosperini, Francesco Saccà, Cinzia Cordioli, Antonio Cortese, Fabio Buttari, Simona Pontecorvo, Assunta Bianco, Serena Ruggieri, Shalom Haggiag, Vincenzo Brescia Morra, Ruggero Capra, Diego Centonze, Giancarlo Di Battista, Elisabetta Ferraro, Ada Francia, Simonetta Galgani, Claudio Gasperini, Enrico Millefiorini, Massimiliano Mirabella & Carlo Pozzilli. (2016) Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-naïve patients with multiple sclerosis. Journal of Neurology 264:2, pages 284-294.
Crossref
Crossref
Manolo E. Beelke, Paola Antonini & Michael F. Murphy. (2016) Evolving landscapes in multiple sclerosis research: adaptive designs and novel endpoints. Multiple Sclerosis and Demyelinating Disorders 1:1.
Crossref
Crossref
Tjalf Ziemssen, Raimar Kern & Christian Cornelissen. (2015) The PANGAEA study design – a prospective, multicenter, non-interventional, long-term study on fingolimod for the treatment of multiple sclerosis in daily practice. BMC Neurology 15:1.
Crossref
Crossref
Olaf Stüve & Gary R Cutter. (2015) Multiple sclerosis drugs: how much bang for the buck?. The Lancet Neurology 14:5, pages 460-461.
Crossref
Crossref
Olga Ciccarelli & Jeremy Chataway. (2014) We can compare the relative efficacy of multiple sclerosis medications by examining the results of independent clinical trials: No. Multiple Sclerosis Journal 21:1, pages 37-38.
Crossref
Crossref
Alice Laroni, Davide Brogi, Vincenzo Brescia Morra, Leonello Guidi, Carlo Pozzilli, Giancarlo Comi, Alessandra Lugaresi, Renato Turrini, Debora Raimondi, Antonio Uccelli & Giovanni Luigi Mancardi. (2014) Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial. BMC Neurology 14:1.
Crossref
Crossref
Jerome J. GraberSuhayl Dhib-Jalbut. (2014) Biomarkers of Interferon Beta Therapy in Multiple Sclerosis. Journal of Interferon & Cytokine Research 34:8, pages 600-604.
Crossref
Crossref
Per Soelberg Sorensen. (2014) Effects of fingolimod in relapsing-remitting multiple sclerosis. The Lancet Neurology 13:6, pages 526-527.
Crossref
Crossref
Luca Prosperini, Chiara Rosa Mancinelli, Laura De Giglio, Floriana De Angelis, Valeria Barletta & Carlo Pozzilli. (2013) Interferon beta failure predicted by EMA criteria or isolated MRI activity in multiple sclerosis. Multiple Sclerosis Journal 20:5, pages 566-576.
Crossref
Crossref
Ron Milo & Ariel Miller. (2014) Revised diagnostic criteria of multiple sclerosis. Autoimmunity Reviews 13:4-5, pages 518-524.
Crossref
Crossref
Francesco Patti & Carlos Vila. (2014) Symptoms, Prevalence and Impact of Multiple Sclerosis in Younger Patients: A Multinational Survey. Neuroepidemiology 42:4, pages 211-218.
Crossref
Crossref
Bernard M.J. Uitdehaag. 2014. Multiple Sclerosis and Related Disorders. Multiple Sclerosis and Related Disorders
393
404
.
Matthew McCoyd. (2013) Update on Therapeutic Options for Multiple Sclerosis. Neurologic Clinics 31:3, pages 827-845.
Crossref
Crossref
Bianca Weinstock-Guttman, Murali Ramanathan & Robert ZivadinovCarlo PozzilliLuca Prosperini. 2013. Personalized Management of Multiple Sclerosis. Personalized Management of Multiple Sclerosis
108
122
.
Patricia K. Coyle. (2013) Switching Therapies in Multiple Sclerosis. CNS Drugs 27:4, pages 239-247.
Crossref
Crossref
Daniel SelchenVirender BhanGregg BlevinsVirginia DevonshirePierre DuquetteFrancois Grand’MaisonMarcelo KremenchutzkyYves LapierreDavid LiSarah Jane von RiedemannMark Freedman. (2012) MS, MRI, and the 2010 McDonald criteria. Neurology 79:23_supplement_2.
Crossref
Crossref
Margitta T Kampman, Linn H Steffensen, Svein I Mellgren & Lone Jørgensen. (2012)
Effect of vitamin D
3
supplementation on relapses, disease progression, and measures of function in persons with multiple sclerosis: exploratory outcomes from a double-blind randomised controlled trial
. Multiple Sclerosis Journal 18:8, pages 1144-1151.
Crossref
Crossref
Gary R Cutter. (2012) Statistical cures and other fallacies. Multiple Sclerosis Journal 18:4, pages 387-390.
Crossref
Crossref
Joep Killestein, Richard A Rudick & Chris H Polman. (2011) Oral treatment for multiple sclerosis. The Lancet Neurology 10:11, pages 1026-1034.
Crossref
Crossref
Mark Sanford & Katherine A. Lyseng-Williamson. (2011) Subcutaneous Recombinant Interferon-β-1a (Rebif®). Drugs 71:14, pages 1865-1891.
Crossref
Crossref